Small private biotechs raise money in mostly early-stage financing

14 Jun 2023

VaccineExecutive ChangeIPO

A trio of biotechs is looking to raise funds, to either kick operations off or to build up resources. Moat Biotechnology , a biotech out of Oklahoma City focusing on intranasal or inhaled adenovirus vaccines, announced Tuesday that it raised $6.5 million in its first close — after launching the company and kicking off an initial funding round back in September. Its co-founders — Scott Rollins and Russell Rother — are former Alexion executives, according to their LinkedIn profiles. Rollins, listed as one of Alexion’s co-founders and former head of drug development, left the company in 2008. Rother, Alexion’s former science chief, left in 2010.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Moat Biotechnology Corp.Alexion Pharma Nordics AB (Sweden)

Indications

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.